narmafotinib + mFOLFIRINOX

Narmafotinib + mFOLFIRINOX is an investigational combination regimen composed of **narmafotinib** (AMP945), a selective, orally bioavailable focal adhesion kinase (FAK) inhibitor, and **mFOLFIRINOX**, a chemotherapy protocol consisting of oxaliplatin, irinotecan, leucovorin, and 5-fluorouracil administered in modified doses. Narmafotinib acts by inhibiting FAK, a non-receptor tyrosine kinase that plays a central role in tumor cell survival, proliferation, migration, and resistance to chemotherapy, as well as modulating the tumor microenvironment by reducing fibrosis and immunosuppression. mFOLFIRINOX is used as a cytotoxic backbone, targeting rapidly dividing cancer cells through multiple mechanisms. The primary indication under investigation is **metastatic pancreatic cancer**, with clinical evaluation in Phase 1 and 2 trials. The combination aims to improve chemotherapy response and progression-free survival in a disease with historically limited treatment efficacy[2][3][5].